Secondary outcomes
depression, forgetfulness, Anxiety, Pain
SECONDARY
The secondary objectives are to compare between patients with the web-application support and patients with standard support:
The rate of adherence failure of adjuvant hormone therapy at 6 months, defined similarly as for primary endpoint.The adherence rate to adjuvant hormone therapy at 6 and 18 months, according to the MMSA8 adherence score, assessed 6 and 18 months after initiation of hormone therapy and the proportions of patients with “Low adherence” (score < 6), “medium adherence” (score ≤ 6 and < 8) and “high adherence” (score = 8), at each time. For patients categorized in “Low” or “Medium” adherence, the proportion of patients for whom the breast nurse and/or oncologist were warned.Pain scores according to the Brief Pain Inventory (BPI), at baseline and 18 months after the start of hormone therapy, and according to the numerical scale at each consultation at the center.Quality of life scores at inclusion, 6 months and 18 months, according to the EORTC QLQ-C30 self-questionnaire and the BR23 additional module.Anxiety and depression scores at baseline, 6 and 18 months, according to the HADS scale.Return to work and/or daily activities, through.
the proportion of patients who practice a professional activity 18 months after the hormone therapy start among patients of working age and in activity before the diagnosis of their breast cancer;Return to work and modalities (part-time, adaptation of the workstation…).Patient satisfaction with their support during the first 18 months of hormone therapy, using a visual analog scale (VAS).Number of calls from patients to the hospital breast nurse over 18 months.Number of appointments proposed with the patient’s oncologist in case of low adherence.Number of appointments with the patient’s oncologist (excluding SCP) related to hormone therapy.In addition, for patients in the experimental arm only, the appropriation, the ease of use and the degree of satisfaction of patients using the web-application, as well as the actions taken in case of poor adherence or non-adherence to hormone therapy will be evaluated with:
The number of connections to the web-application.The measurement of the usability of the web-application via the System Usability Scale (SUS).The number of patients who received practical advices to reduce the risk of forgetfulness.The number of contacts with the hospital breast nurse (via web-application or phone), with the aim of better understanding the difficulties encountered in terms of adherence and offering assistance to the patient.